

## Coagulation Factors Expert Panel August 21–22, 2019 USP – U.S., Rockville

## Agenda - Draft

|                              | nticipated Outcomes<br>vided under each agenda item.   |   |
|------------------------------|--|---|
| Attendees<br>Attendee list µ | provided on the day of the meeting   |   |
| Day 1<br>Wednesday,          | August 21, 2019  |   |
| 8:15 a.m.                    | Arrive at USP, register and check in   |   |
|                              | CLOSED TO ALL OBSERVERS AND GOVERNMENT LIAISONS  |   |
| 8:30 a.m.                    | <ol> <li>Closed Procedural Matters and Standards of Conduct         <ul> <li>Welcome, Opening Remarks, Introduction</li> <li>Conflicts of Interest, Confidentiality, Code of Ethics</li> <li>Review of Agenda for Specific Conflicts of Interest/Need for Recusal</li> </ul> </li> <li>END CLOSED SESSION</li> </ol> | Dr. Alai<br>Ms. Casino<br>Dr. Alai                                    |
| 8:45 a.m.                    | 2. Open Procedural Matters   |   |
| 0.40 a.m.                    | <ul> <li>a. Welcome</li> <li>b. Meeting Center Announcements</li> <li>c. Recording Policy and any other Procedural<br/>Announcements</li> <li>d. Roll Call and Introduction of Members, Government<br/>Liaisons, Staff, and Observers</li> <li>e. Establish Quorum</li> <li>f. Approval of Agenda</li> </ul>         | Dr. Alai<br>Ms. Fletcher<br>Ms. Casino<br>All<br>Dr. Alai<br>Dr. Alai |
| 9:00 a.m.<br>Goal: Introdu   | g. Action Items from Previous Meeting  3. Introduction of Bioassay Principles uce how statistical validity of bioassays is determined a. Bioassay Principles b. Discussion   | Ms. Casino<br>Mr. Walfish<br>All                                      |



|                      | Basis of Clotting and Chromogenic Assays sics of clotting and chromogenic methods   | /                     |
|----------------------|---|-----------------------|
|                      | Review Basics of Clotting and Chromogenic     Methods   | Dr. Rosén             |
|                      | b. Discussion   | All                   |
| 10:00 a.m.           | Break   |                       |
|                      | Potency Labeling of FVIII and FIX Products ground on potency assignment, including history of assay discrepancies ectives | s and                 |
| · , , ,              | <ul><li>a. Overview of Potency Labeling</li><li>b. Discussion</li></ul>   | Dr. Gray<br>All       |
|                      | D. Disoussion   | 7 111                 |
|                      | Assays for FVIII rrent assays for FVIII   |                       |
|                      | a. Overview of Clotting Test Methods  | Dr. Gray              |
|                      | <ul><li>b. Chromogenic Method Details and Differences</li><li>c. Discussion</li></ul>                                     | Dr. Rosén<br>All      |
| 11:30 a.m. <b>7.</b> | Assays for FIX  |                       |
| Goal: Review cui     | rrent assays for FIX  | D., C.,               |
|                      | <ul><li>a. Overview of Clotting Test Methods</li><li>b. Chromogenic Method Details and Differences</li></ul>              | Dr. Gray<br>Dr. Rosén |
|                      | c. Discussion   | All                   |
| 12:00 p.m. <b>Lu</b> | nch & Group Photo   |                       |
| 1:00 p.m. <b>8.</b>  | Case Study: Analytical Chapter Development  |                       |
| Goal: Review a d     | case study on development of a complex USP General Chapter  |                       |
|                      | a. USP General Chapter <129> Development  | Dr. Carrick           |
|                      | <ul><li>b. Reference Standard Development</li><li>c. Discussion</li></ul>   | Dr. Carrick<br>All    |
|                      | c. Discussion   | All                   |
| 1:45 p.m. <b>9.</b>  | Assay Discrepancies for FVIII and FIX   |                       |
| Goal: Understand     | d the issue of assay discrepancies for modified products  | Dr. Crov              |
|                      | <ul><li>a. rFVIII Potency Assignment</li><li>b. rFIX Potency Assignment</li></ul>   | Dr. Gray<br>Dr. Rosén |
|                      | c. Discussion   | All                   |
| 3:15 p.m.            | Break   |                       |



3:45 p.m. 10. Landscape of Current and Upcoming Products Goal: Understand the current and future landscape of products a. Landscape of Products Dr. Jing b. Discussion ΑII 4:00 p.m. 11. Use of Assays in the Clinic Goal: Understand the assays used in the clinic a. Use of Assays in the Clinic Dr. Gray b. Discussion ΑII 12. Wrap-up of Day 1 Dr. Alai 4:45 p.m. Adjourn – Day 1, Transportation to Hotel 5:00 p.m. Day 2 Thursday, August 22, 2019 8:30 a.m. 13. Scope of Work for >1000 General Chapter Goal: Define the scope of work for the >1000 (informational) General Chapter a. Discussion ΑII 10:00 a.m. **Break** 14. Scope of Work for <1000 General Chapter 10:15 a.m. Goal: Define the Scope of work for the <1000 (method) General Chapter a. Discussion ΑII 11:45 a.m. 15. Meeting Summary Dr. Alai a. Meeting Summary b. Reminder of next EC meeting Ms. Casino **Adjourn & Lunch** 12:00 p.m.